Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.3K citations · Full text

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow et al. · New England Journal of Medicine · 2012 · 7.9K citations · Full text

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena et al. · New England Journal of Medicine · 2013 · 6.5K citations

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Jérôme Galon, Anne Costes, Fátima Sánchez‐Cabo et al. · Science · 2006 · 6.3K citations

Tumor Immunology, Cancer Immunosurveillance, Adaptive Immune Response +12

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade

Pornpimol Charoentong, Francesca Finotello, Mihaela Angelova et al. · Cell Reports · 2017 · 5.2K citations · Full text

Machine Learning, Genomic Landscapes, Immunology +16